HBDDE biochemical

HBDDE

CATALOG #
AAA227786

PRODUCT SYNONYMS

HBDDE; HBDDE biochemical

PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	154675-18-0
Targets&IC50	PKCalpha:43 uM (IC50), PKCgamma:50 uM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	HBDDE (50 uM; 5 hours) treatment reduces cell viability significantly by ~70%. HBDDE exhibits a marked increase in caspase-3 activity[1]. Cell Viability Assay[1]Cell Line: Cerebellar granule cells Concentration: 50 uM Incubation Time: 5 hours. Result: Reduced cell viability significantly by ~70%.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Thalidomide-NH-C6-NH-Boc, CAS 2093536-13-9



Structure
Thalidomide-NH-C6-NH-Boc, CAS 2093536-13-9

ADDITIONAL INFORMATION

Related Product Information for HBDDE biochemical	HBDDE, a derivative of Ellagic acid, is an isoform-selective PKCalpha and PKCgamma inhibitor with IC 50 s of 43 uM and 50 uM, respectively. HBDDE shows selective for PKCalpha/PKCgamma over PKCdelta, PKCbetaI and PKCbetaII isozymes. HBDDE induces neuronal apoptosis.
References	1. Mette Ishoey, et al. Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.ACS Chem Biol. 2018 Mar 16;13(3):553-560.